Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Breast Neoplasms 320Leukemia, Myeloid, Acute 266Multiple Myeloma 227Carcinoma, Non-Small-Cell Lung 224Prostatic Neoplasms 202Neoplasms 196Lymphoma 191Colorectal Neoplasms 184Melanoma 178Leukemia 170Recurrence 163Pancreatic Neoplasms 163Precursor Cell Lymphoblastic Leukemia-Lymphoma 160Lung Neoplasms 150Glioblastoma 134Neoplasm Metastasis 132Lymphoma, Non-Hodgkin 128Ovarian Neoplasms 123Leukemia, Lymphocytic, Chronic, B-Cell 120Myelodysplastic Syndromes 117Lymphoma, Large B-Cell, Diffuse 110Lymphoma, Mantle-Cell 108Carcinoma, Hepatocellular 103Lymphoma, Follicular 99Stomach Neoplasms 96Carcinoma, Renal Cell 89Hodgkin Disease 88Brain Neoplasms 88Sarcoma 84Burkitt Lymphoma 75

Interventions

tildrakizumab 1pembrolizumab 1enzalutamide 1N-(2-(2,3-difluoro-6-benzylthio)-6-(3,4-dihydroxybutan-2-yloxy)pyrimidin-4-yl)azetidine-1-sulfonamide 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × Metastatic Castration Resistant Prostate Cancer × Clear all
NCT03177187 2024-09-26

ACE

Institute of Cancer Research, United Kingdom

Phase 1/2 Terminated
30 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer

NCT04458311 2024-04-25

ACTIon

Institute of Cancer Research, United Kingdom

Phase 1/2 Terminated
13 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer

NCT03658447 2023-07-28

PRINCE

Peter MacCallum Cancer Centre, Australia

Phase 1/2 Completed
37 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡